Industry News（Jan 2024 to May 2024）

Abstract

This review provides an overview of the key developments and milestones in organoid and organ-on-a-chip technologies from January to May 2024, as reported in the industry news. The period witnessed significant advancements including regulatory approvals, clinical trial initiations, and strategic partnerships that underscore the growing influence of these technologies in medical research and treatment strategies. Notable highlights include the approval of MedGenCell's PD-1 knockout T cell therapy for lung cancer under the IND application, MIMETAS's participation in the GRIPonMASH program for metabolic disease modeling, and the successful hosting of several global conferences that gathered leading experts in the field. Additionally, funding rounds such as DarkJade Sciences' Pre-A financing and strategic collaborations, like that between Regenerative Bio and Signet Therapeutics, reflect robust industry engagement and investment. These developments collectively push forward the frontiers of healthcare, emphasizing organoid and organ-on-a-chip technologies' pivotal roles in enhancing disease modeling, drug testing, and therapeutic interventions.